外科医生专科在恶性卵巢生殖细胞肿瘤管理与生存中的作用:一项基于人群的研究
该基于人群的回顾性队列研究纳入加拿大安大略省1996至2020年登记的363例成人恶性卵巢生殖细胞肿瘤患者,比较由普通妇科医生与妇科肿瘤医生手术者的治疗和生存。妇科肿瘤医生组II-IV期比例更高(27.5% vs 3.9%,p<0.001),化疗比例更高(64.4% vs 37.4%,p<0.0001);5年总生存率分别为90%与93%(p=0.39),外科医生专科与全因死亡无独立关联(HR 1.04,95%CI 0.51-2.15,p=0.91)。
要点
- 妇科肿瘤医生组II-IV期比例更高(27.5% vs 3.9%,p<0.001),化疗比例更高(64.4% vs 37.4%,p<0.0001)。
- 妇科肿瘤医生组与普通妇科医生组5年总生存率分别为90%与93%(p=0.39)。
- 外科医生专科与全因死亡无独立关联(HR 1.04,95%CI 0.51-2.15,p=0.91)。
核心结论
- 在该组恶性卵巢生殖细胞肿瘤患者中,由妇科肿瘤医生手术与由普通妇科医生手术相比,5年总生存率无显著差异。
- 尽管普通妇科医生组具有低风险特征,但其生存率低于预期;作者认为需进一步探索其原因以及疑似恶性卵巢生殖细胞肿瘤患者是否能从妇科肿瘤医生的早期评估中获益以实现最佳管理。
研究设计与样本
- 本研究为基于人群的回顾性队列研究,纳入加拿大安大略省省级癌症登记处1996至2020年登记的年龄≥18岁的恶性卵巢生殖细胞肿瘤患者。
- 共纳入363例患者,其中160例(44%)由妇科肿瘤医生手术,203例(56%)由普通妇科医生手术;比较两组基线特征、手术与化疗治疗,并采用Cox比例风险模型分析外科医生专科与总生存的关联。
主要发现
- 妇科肿瘤医生组II-IV期比例高于普通妇科医生组(27.5% vs 3.9%,p<0.001)。
- 妇科肿瘤医生组化疗比例高于普通妇科医生组(64.4% vs 37.4%,p<0.0001)。
- 妇科肿瘤医生组与普通妇科医生组5年总生存率分别为90%与93%(p=0.39)。
- Cox比例风险模型显示,与死亡风险增加相关的因素为诊断时年龄较大(HR 1.09,95%CI 1.07-1.12)和化疗(HR 3.12,95%CI 1.44-6.75)。
- 外科医生专科与全因死亡无独立关联(HR 1.04,95%CI 0.51-2.15,p=0.91)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study is to describe management and survival in adult patients with malignant ovarian germ cell tumors (MOGCT) undergoing surgery by general gynecologists (GG) versus gynecologic oncologists (GO). METHODS: This is a population-based retrospective cohort study, including patients (age ≥ 18 years old) with MOGCT identified in the provincial cancer registry of Ontario, (1996-2020). Baseline characteristics, surgical and chemotherapy treatment were compared between those with surgery by GG or GO. Cox proportional hazards (CPH) model was used to determine if surgeon specialty was associated with overall survival (OS). RESULTS: Overall, 363 patients were included. One-hundred and sixty (44%) underwent surgery by GO and 203 (56%) by GG. There were higher rates of stage II-IV in the GO group (27.5% vs 3.9%, p < 0.001, and higher proportion of chemotherapy (64.4% vs 37.4%, p < 0.0001). Five-year OS was 90% and 93% in the GO vs GG groups, respectively (p = 0.39). CPH model showed factors associated with increased risk of death were older age at diagnosis (HR 1.09, 95% CI 1.07-1.12) and chemotherapy (HR 3.12, 95% CI 1.44-6.75). Surgeon specialty was not independently associated with all-cause death (HR 1.04, 95% 0.51-2.15, p = 0.91). CONCLUSIONS: In this group of MOGCT, 5-year OS was not significantly different between patients having surgery by GO compared to GG. Nevertheless, survival rates were lower than expected in the GG group despite their low-risk features. Further exploration is warranted regarding the reasons for this and whether patients with suspected MOGCT may benefit from early assessment by GO for optimal management.
引用
- Salman L, Covens A, Vicus D, et al. The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study. Gynecol Oncol. 2024. PMID: 38417208. doi:10.1016/j.ygyno.2024.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。